Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes
Diabetes Care · 2026
DOI: 10.2337/dc25-1619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2026. Verfasst von Sérgio R R Decker und 6 weiteren Autor:innen. Beteiligte Einrichtung: Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Medicare, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Identifying social and economic factors associated with initiation of semaglutide or tirzepatide may inform strategies to support equitable uptake. RESEARCH DESIGN AND METHODS A cross-sectional study was conducted using 100% of Medicare claims of patients ≥65 years with type 2 diabetes mellitus (T2DM). The outcome was initiation of semaglutide or tirzepatide. We calculated adjusted odds ratios (aORs) for each exposure (self-reported race and ethnicity, dual enrollment in Medicare and Medicaid, rurality, and social vulnerability index), accounting for demographic and clinical characteristics. RESULTS Among 13,922,387 patients with T2DM, 673,776 (4.8%) initiated semaglutide or tirzepatide in 2023. Minoritized racial and ethnic identity (e.g., non-Hispanic Black compared with White; aOR 0.72; 95% CI 0.71–0.72), dual enrollment (aOR 0.90; 0.89–0.91), and residence in the most versus least vulnerable socially vulnerable neighborhoods (aOR 0.93; 0.92–0.93) were associated with lower initiation. CONCLUSIONS Minoritized racial and ethnic identity and adverse socioeconomic factors were associated with lower odds of initiation among Medicare beneficiaries with T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA.
- Harvard Medical School, Boston, MA.
- Department of Internal Medicine and MOVE Outcomes Research Lab, Moinhos de Vento Hospital, Porto Alegre, Brazil.
- Department of Health Promotion and Behavioral Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Hakubi Center, Kyoto University, Kyoto, Japan.
- Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
ORCID-Profile: Sérgio R R Decker, Chiadi E Ndumele, Sadiya S Khan, Dhruv S Kazi
Zitieren
APA
Decker, S. R. R., Chaudhary, R. S., Inoue, K., Song, Y., Ndumele, C. E., Khan, S. S., & Kazi, D. S. (2026). Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc25-1619
Vancouver
Decker SRR, Chaudhary RS, Inoue K, Song Y, Ndumele CE, Khan SS, et al. Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. Diabetes Care. 2026. doi:10.2337/dc25-1619
BibTeX
@article{Decker2026,
author = {Decker, Sérgio R R and Chaudhary, Richard S and Inoue, Kosuke and Song, Yang and Ndumele, Chiadi E and Khan, Sadiya S and Kazi, Dhruv S},
title = {Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc25-1619}
}
EUVIMED